Question 1

What is the share price of REMUS PHARMACEUTICALS L today?

Accepted Answer

REMUS PHARMACEUTICALS L (REMUS) is trading at ₹880.6. The price shown is the latest available from the exchange feed and updates through the trading session.

Question 2

What is REMUS’s P/E ratio versus the sector?

Accepted Answer

REMUS trades at a P/E of 44.0. Its industry median is shown alongside it in Key Stats, so you can see at a glance whether the stock is priced above or below the businesses it competes with. A lower P/E is not automatically cheaper — it can also reflect slower expected growth.

Question 3

What is REMUS’s dividend yield?

Accepted Answer

REMUS has a dividend yield of 0.11%, based on dividends declared over the last twelve months against the current price. The full dividend history is on the News & Filings tab.

Question 4

What is REMUS’s 52-week high and low?

Accepted Answer

REMUS has traded between ₹860 and ₹890 over the past year. The Trading Data block shows where the current price sits inside that band.

Question 5

What is the market capitalisation of REMUS PHARMACEUTICALS L?

Accepted Answer

REMUS PHARMACEUTICALS L has a market capitalisation of ₹1,062 crore.

Question 6

What is REMUS’s return on equity?

Accepted Answer

REMUS reports a return on equity of 8.5%. ROE measures profit generated per rupee of shareholder capital, and is most meaningful compared against others in —.

Question 7

Who are REMUS’s competitors?

Accepted Answer

The Peers block on this page lists other — companies with their price, P/E and market capitalisation. The Valuation tab compares multiples against the industry median in more depth.

Question 8

What is REMUS’s promoter holding?

Accepted Answer

Promoters hold 70.95% of REMUS. The Ownership tab shows the full shareholding pattern — promoter, FII, DII and public — and how each has moved across recent quarters.

Question 9

Which indices include REMUS?

Accepted Answer

Index membership is listed in the Context block on this page, along with the weight REMUS carries in each. That weight is what determines how much passive money tracks the stock.

Question 10

Is REMUS PHARMACEUTICALS L a good buy?

Accepted Answer

We do not publish buy or sell calls. What this page gives you instead is the evidence: our Value & Investment Index for where the price sits against its own history, the Fundamental Strength Index for the quality of the business, an investment checklist of criteria applied to every stock, and pros and cons generated from REMUS’s own numbers. The judgement is yours.

Revenue	₹94 crore
Net profit	₹25 crore
Operating margin	32%
EPS	₹20.97

REMUS

REMUS

Fundamental Strength Index

Profitability

Growth

Segment Results

Working Capital & Efficiency

REMUS financial summary